The Phase II (NCT03071874) study investigating the use of vistusertib, the oral dual mTORC1/mTORC2 inhibitor in NF2-related schwannomatosis patients with either progressive or symptomatic meningiomas failed to meet the primary endpoint of a 20% volume decrease [126]. This evidence concerns the gene NF2 and meningioma.